Sirtuin 6 Expression and Inflammatory Activity in Diabetic Atherosclerotic Plaques: Effects of Incretin Treatment
Open accessThe DOI matches its Crossref record; 38 of the 40 references it cites were found in a registry or an index.
Abstract
The role of sirtuin 6 (SIRT6) in atherosclerotic progression of diabetic patients is unknown. We evaluated SIRT6 expression and the effect of incretin-based therapies in carotid plaques of asymptomatic diabetic and nondiabetic patients. Plaques were obtained from 52 type 2 diabetic and 30 nondiabetic patients undergoing carotid endarterectomy. Twenty-two diabetic patients were treated with drugs that work on the incretin system, GLP-1 receptor agonists, and dipeptidyl peptidase-4 inhibitors for 26 ± 8 months before undergoing the endarterectomy. Compared with nondiabetic plaques, diabetic plaques had more inflammation and oxidative stress, along with a lesser SIRT6 expression and collagen content. Compared with non-GLP-1 therapy–treated plaques, GLP-1 therapy–treated plaques presented greater SIRT6 expression and collagen content, and less inflammation and oxidative stress, indicating a more stable plaque phenotype. These results were supported by in vitro observations on endothelial progenitor cells (EPCs) and endothelial cells (ECs). Indeed, both EPCs and ECs treated with high glucose (25 mmol/L) in the presence of GLP-1 (100 nmol/L liraglutide) presented a greater SIRT6 and lower nuclear factor-κB expression compared with cells treated only with high glucose. These findings establish the involvement of SIRT6 in the inflammatory pathways of diabetic atherosclerotic lesions and suggest its possible positive modulation by incretin, the effect of which is associated with morphological and compositional characteristics of a potential stable plaque phenotype.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In diabetic patients treated with GLP-1-based therapy, the protein level of SIRT6 in asymptomatic plaques was significantly increased and TNF-α and MMP-9 levels in lesions were significantly reduced compared with diabetic patients without treatment [8].”
From Anti-Inflammatory Effects of GLP-1-Based Therapies beyond Glucose Control (2016) · cites this paper as [8]
In the citing paper
“Liraglutide (100 nM) treatment increased SIRT6 expression and reduced NF-κB expression compared with only high glucose-treated endothelial cells.”
From Anti-Inflammatory Effects of GLP-1-Based Therapies beyond Glucose Control (2016) · cites this paper as [8]
In the citing paper
“More importantly, compared with non-GLP-1RA/DPP-4i-treated plaques, GLP-1RA/DPP-4i-treated plaques presented greater SIRT6 expression and collagen content, with less inflammation and oxidative stress, indicating a more stable plaque phenotype and suggesting that GLP-1RAs can reduce plaque vulnerability [58].”
From Protection against stroke with glucagon-like peptide-1 receptor agonists: a comprehensive review of potential mechanisms (2022) · cites this paper as [58]
In the citing paper
“Compared with non-diabetic plaques, diabetic plaques had more inflammation and oxidative stress, along with a lower sirtuin (SIRT)6 expression and less interstitial collagen content.”
From Protection against stroke with glucagon-like peptide-1 receptor agonists: a comprehensive review of potential mechanisms (2022) · cites this paper as [58]
In the citing paper
“More importantly, compared with non-GLP-1RA/DPP-4i-treated plaques, GLP-1RA/DPP-4i-treated plaques presented greater SIRT6 expression and collagen content, with less inflammation and oxidative stress, indicating a more stable plaque phenotype and suggesting that GLP-1RAs can reduce plaque vulnerability [58].”
From Protection against stroke with glucagon-like peptide-1 receptor agonists: a comprehensive review of potential mechanisms (2022) · cites this paper as [58]
Citations
Cites
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus
Scirica, B. M., Bhatt, D. L., Braunwald, E., Steg, P. G., Davidson, J., Hirshberg, B., Ohman, P., Frederich, R., Wiviott, S. D., Hoffman, E. B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1307684 · Cited by 3,470
Grundy, S. M., Benjamin, I. J., Burke, G. L., Chait, A., Eckel, R. H., Howard, B. V., Mitch, W., Smith, S. C., & Sowers, J. R. (1999) · Circulation · doi:10.1161/01.cir.100.10.1134 · Cited by 2,698
Alogliptin after acute coronary syndrome in patients with type 2 diabetes
White, W. B., Cannon, C. P., Heller, S. R., Nissen, S. E., Bergenstal, R. M., Bakris, G. L., Perez, A. T., Fleck, P. R., Mehta, C. R., Kupfer, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305889 · Cited by 2,502
Diabetes and Vascular Disease: Pathophysiology, Clinical Consequences, and Medical Therapy: Part I
Creager, M. A., Lüscher, T. F., of, P. W. T. A., Cosentino, F., & Beckman, J. A. (2003) · Circulation · doi:10.1161/01.cir.0000091257.27563.32 · Cited by 1,650
Moghissi, E. S., Korytkowski, M. T., DiNardo, M., Einhorn, D., Hellman, R., Hirsch, I. B., Inzucchi, S. E., Ismail-Beigi, F., Kirkman, M. S., & Umpierrez, G. E. (2009) · Diabetes Care · doi:10.2337/dc09-9029 · Cited by 1,444
Michishita, E., Park, J. Y., Burneskis, J. M., Barrett, J. C., & Horikawa, I. (2005) · Molecular Biology of the Cell · doi:10.1091/mbc.e05-01-0033 · Cited by 1,364
SIRT6 is a histone H3 lysine 9 deacetylase that modulates telomeric chromatin
Michishita, E., McCord, R. A., Berber, E., Kioi, M., Padilla-Nash, H., Damian, M., Cheung, P., Kusumoto, R., Kawahara, T. L. A., Barrett, J. C., et al. (2008) · Nature · doi:10.1038/nature06736 · Cited by 1,111 · cited 1×
“GLP-1 levels (Active GLP-1 [7-36] Specific ELISA Kit; Epitope Diagnostics) were measured after an overnight fast (at 8:00 A.”
MethodKawahara, T. L. A., Michishita, E., Adler, A. S., Damian, M., Berber, E., Lin, M., McCord, R. A., Ongaigui, K. C. L., Boxer, L. D., Chang, H. Y., et al. (2009) · Cell · doi:10.1016/j.cell.2008.10.052 · Cited by 1,090
Arakawa, M., Mita, T., Azuma, K., Ebato, C., Goto, H., Nomiyama, T., Fujitani, Y., Hirose, T., Kawamori, R., & Watada, H. (2010) · Diabetes · doi:10.2337/db09-1694 · Cited by 548 · cited 1×
“GLP-1 levels (Active GLP-1 [7-36] Specific ELISA Kit; Epitope Diagnostics) were measured after an overnight fast (at 8:00 A.”
Method
Cited by
Items 101–196 of 196
L-Carnitine: An Antioxidant Remedy for the Survival of Cardiomyocytes under Hyperglycemic Condition
Vacante, F., Senesi, P., Montesano, A., Frigerio, A., Luzi, L., & Terruzzi, I. (2018) · Journal of Diabetes Research · doi:10.1155/2018/4028297 · Cited by 29
“demonstrated that SIRT6 protein expression is downregulated in atherosclerotic plaques of diabetics, and this defect is linked to the chronic oxidative stress condition [6].”
BackgroundThe Anti-Inflammatory Effect of Novel Antidiabetic Agents
Theofilis, P., Sagris, Μ., Oikonomou, E. K., Antonopoulos, A. S., Siasos, G., Tsioufis, K., & Tousoulis, D. (2022) · Life · doi:10.3390/life12111829 · Cited by 35
“A SIRT6 level crease has been previously asso i ted with the downregulation of proinflammator g nes expression [79,80].”
BackgroundYang, J., Dou, G., Tesche, C., Cecco, C. N. D., Jacobs, B. E., Schoepf, U. J., & Chen, Y. (2019) · BMC Cardiovascular Disorders · doi:10.1186/s12872-019-1016-4 · Cited by 29
GLP-1 Receptor Agonists and Coronary Arteries: From Mechanisms to Events
de Mortanges, A. P., Sinaci, E., Salvador, D., Bally, L., Muka, T., Wilhelm, M., & Bano, A. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.856111 · Cited by 26
Aging and pathological aging signatures of the brain: through the focusing lens of SIRT6
Stein, D., Mizrahi, A., Golova, A., Saretzky, A., García-Venzor, A., Slobodnik, Z., Kaluski, S., Einav, M., Khrameeva, E. E., & Toiber, D. (2021) · Aging · doi:10.18632/aging.202755 · Cited by 28
“Particularly, the absence of SIRT6 results in neurodegeneration [10], heart disease [11], inflammation [12], diabetes [13], and more.”
BackgroundThe Role of Increased Expression of Sirtuin 6 in the Prevention of Premature Aging Pathomechanisms
Dzidek, A., Czerwińska‐Ledwig, O., Żychowska, M., Pilch, W., & Piotrowska, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24119655 · Cited by 25
“Balestrieri et al. [37] demonstrated reduced SIRT6 expression and lower interstitial collagen content in cells obtained from homogenates of atherosclerotic plaques from the carotid arteries of people with diabetes compared to plaques obtained from people without diabetes.”
BackgroundResultInfluentialCombating cellular senescence by sirtuins: Implications for atherosclerosis
Ma, S., Fan, L., & Cao, F. (2018) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2018.06.011 · Cited by 24
Katakami, N., Mita, T., Irie, Y., Takahara, M., Matsuoka, T., Gosho, M., Watada, H., Shimomura, I., & Collaborators, O. B. O. T. S. P. S. O. I.-M. T. E. (. (2018) · Cardiovascular Diabetology · doi:10.1186/s12933-018-0666-3 · Cited by 22
“Our study was also consistent with another previous study using samples from asymptomatic patients undergoing carotid endarterectomy that revealed that incretin therapy–treated plaques presented with higher collagen content and less inflammation and oxidative stress than non-incretin–treated plaques, indicating a more…”
ResultSong, T., Fu, Y., Wang, Y., Li, W., Zhao, J., Wang, X., Wang, H., Zhao, Y., & Fu, X. (2021) · BMC Cardiovascular Disorders · doi:10.1186/s12872-020-01839-w · Cited by 28
“In addition, based on the existing evidence, ISR is a complex inflammatory and reparative reaction to vessel injury following stent implantation arising from neointimal hyperplasia, and there is evidence revealing the involvement of regulators which serve as pro-inflammation roles (such as sirtuins, microRNAs (miRNAs)…”
BackgroundArcangeli, A., Lastraioli, E., Piccini, B., D’Amico, M., Lenzi, L., Pillozzi, S., Calabrese, M., Toni, S., & Arcangeli, A. (2017) · Frontiers in Endocrinology · doi:10.3389/fendo.2017.00278 · Cited by 22
Sirt6 regulates autophagy in AGE-treated endothelial cells via KLF4
Tong, J., Ji, B., Gao, Y., Lin, H., Ping, F., Chen, F., & Liu, X. (2021) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2021.12.020 · Cited by 18
Wei, Z., Bai, J., Dai, Q., Wu, H., Qiao, S., Xu, B., & Wang, L. (2018) · BMC Cardiovascular Disorders · doi:10.1186/s12872-018-0924-z · Cited by 19
Mitochondrial Sirtuins in Chronic Degenerative Diseases: New Metabolic Targets in Colorectal Cancer
Colloca, A., Balestrieri, A., Anastasio, C., Balestrieri, M. L., & D’Onofrio, N. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23063212 · Cited by 21
“of oxidative and inflammatory processes in endothelial cells [43].”
BackgroundSelf-citationIncretin treatment and atherosclerotic plaque stability: Role of adiponectin/APPL1 signaling pathway
Barbieri, M., Marfella, R., Esposito, A., Rizzo, M. R., Angellotti, E., Mauro, C., Siniscalchi, M., Chirico, F., Caiazzo, P., Furbatto, F., et al. (2016) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2016.10.001 · Cited by 19
Self-citationClinical Implications of the Coexistence of Anemia and Diabetes Mellitus in the Elderly Population
Michalak, S. S., Wolny-Rokicka, E. I., Nowakowska, E., Michalak, M., & Gil, L. (2021) · Journal of Diabetes Research · doi:10.1155/2021/8745968 · Cited by 24
“GLP-1 therapy reduces the inflammation and oxidative stress of atherosclerotic plaque, which probably affects its stability [54].”
BackgroundShen, Z., Yang, Q.-Z., Li, C., Du, L., Sun, X., Liu, Y., Sun, J., Gu, H.-H., Sun, Y.-M., Wang, J., et al. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2018.05.005 · Cited by 18
Zheng, Z., Wang, B., Lv, X., Yao, F., Gao, H., Jin, Z., Liu, Y., Deng, Y. J., Chen, D., Ning, X., et al. (2021) · Experimental Cell Research · doi:10.1016/j.yexcr.2021.112526 · Cited by 20
DNA damage response, a double-edged sword for vascular aging
Zhang, X., Zhao, Q., Wang, T., Long, Q., Sun, Y., Jiao, L., & Gullerová, M. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.102137 · Cited by 21
“SIRT6 is involved in the inflammatory pathways of diabetic atherosclerotic lesions (Balestrieri et al., 2015).”
Diabetes mellitus, frailty and prognosis in very elderly patients with acute coronary syndromes
the LONGEVO-SCA registry investigators, Gual, M., Formiga, F., Ariza‐Solé, A., López‐Palop, R., Sanchís, J. M., Marín, F. R., Vidán, M. T., Martínez‐Sellés, M., Sionís, A., et al. (2019) · Aging Clinical and Experimental Research · doi:10.1007/s40520-018-01118-x · Cited by 17
The Role of Vascular Aging in Atherosclerotic Plaque Development and Vulnerability
Liberale, L., & Camici, G. G. (2019) · Current Pharmaceutical Design · doi:10.2174/1381612825666190830175424 · Cited by 20
Liu, Q., Li, H., Wang, J., Zhong, L., Chen, X., Zhang, R., & Wang, H. (2020) · Experimental Gerontology · doi:10.1016/j.exger.2020.111053 · Cited by 17
Chang-qing, L., Jia, H., & Wang, Z. (2019) · Bioscience Reports · doi:10.1042/bsr20182278 · Cited by 16
Scisciola, L., Rizzo, M. R., Marfella, R., Cataldo, V., Fontanella, R. A., Boccalone, E., Paolisso, G., & Barbieri, M. (2020) · Journal of Cellular Physiology · doi:10.1002/jcp.30185 · Cited by 16
Self-citationCiuceis, C. D., Rosei, C. A., Rossini, C., Caletti, S., Coschignano, M. A., Ferrari‐Toninelli, G., Ragni, G., Cappelli, C., Cerudelli, B., Airó, P., et al. (2018) · High Blood Pressure & Cardiovascular Prevention · doi:10.1007/s40292-018-0279-7 · Cited by 17
Hardoňová, M., Šiarnik, P., Siváková, M., Sucha, B., Penesová, A., Rádiková, Ž., Havranová, A., Imrich, R., Vlček, M., Žitňanová, I., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241311162 · Cited by 16
“GLP-1as reduce hunger mediated by the receptors expressed in the central nervous system and thus cause a modest weight loss [36].”
BackgroundIncretin and glucagon receptor polypharmacology in chronic kidney disease
McFarlin, B. E., Duffin, K. L., & Konkar, A. A. (2024) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00374.2023 · Cited by 17
Phenolic Profiles of Red Wine Relate to Vascular Endothelial Benefits Mediated by SIRT1 and SIRT6
D’Onofrio, N., Martino, E., Chianese, G., Coppola, F., Picariello, L., Luigi Moio, B., Balestrieri, M. L., Angelita Gambuti, B., & Forino, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115677 · Cited by 16
Self-citationHuang, S., Shao, T., Liu, H., Wang, Q., Li, T., & Zhao, Q. (2022) · Cell Death Discovery · doi:10.1038/s41420-022-00903-y · Cited by 16
“SIRT6 expression appears to be downregulated in the atherosclerotic plaque in humans and animal models [53, 54] and in cultured endothelial cells by oxLDL treatment, which can be reversed by the DNMT inhibitor 5-Aza-dc (Fig.”
BackgroundSIRT6 regulates endothelium-dependent relaxation by modulating nitric oxide synthase 3 (NOS3)
Wang, J., Liu, Z., Lü, J., Zou, J., Ye, W., Li, H., Gao, S., & Liu, P. (2023) · Biochemical Pharmacology · doi:10.1016/j.bcp.2023.115439 · Cited by 18
Racis, M., Sobiczewski, W., Stanisławska‐Sachadyn, A., Wirtwein, M., Bluj, E., Nedoszytko, M., Borzyszkowska, J., Limon, J., Rynkiewicz, A., & Gruchała, M. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9051475 · Cited by 15
“can assume that mechanisms underlying chronic atherosclerotic plaque growth differ from pathological processes leading to acute plaque rupture, which may be determined by genetic variants associated with oxidative stress [34].”
BackgroundTherapeutic Targeting of Cellular Stress to Prevent Cardiovascular Disease: A Review of the Evidence
Mooradian, A. D. (2016) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-016-0199-7 · Cited by 15
Biesenbach, P., Heinsen, L. J., Overgaard, K. S., Andersen, T. R., Auscher, S., & Egstrup, K. (2023) · Cardiovascular Therapeutics · doi:10.1155/2023/5126825 · Cited by 13
“Not only GLP-1 receptor agonists [47] but also sodium glucose cotransport 2 inhibitors (SGLT2i) [48] and metformin [49] have shown to increase SIRT6 expression and exhibit antiinflammatory effects on cardiac plaque.”
BackgroundWang, Y., Tong, L., Gu, N., Ma, X., Lu, D., Yu, D., Yu, N., Zhang, J., Li, J., & Guo, X. (2022) · Journal of Diabetes Research · doi:10.1155/2022/8494502 · Cited by 12
“Some hypoglycemic medications have been reported to improve cardiac outcomes, such as incretin [22] and sodium-dependent glucose transporters 2 inhibitor (SGLT2i) [24]; however, the mechanisms are unclear.”
BackgroundStåhle, M. R., Hellberg, S., Virta, J., Liljenbäck, H., Metsälä, O., Li, X., Jauhiainen, M., Saukko, P. J., Ylä‐Herttuala, S., Nuutila, P., et al. (2021) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00465.2020 · Cited by 13
Effect of Liraglutide on Vascular Inflammation Evaluated by [64Cu]DOTATATE
Zobel, E. H., Ripa, R. S., von Scholten, B. J., Curovic, V. R., Díaz, L. J., Hansen, T. W., Rossing, P. R., & Kjær, A. (2021) · Diagnostics · doi:10.3390/diagnostics11081431 · Cited by 12
“Clinical data have demonstrated that liraglutide treatment reduces the levels of the inflammatory marker sCD163 and inflammatory macrophages [21] and one study demonstrated reduced inflammation in carotid plaques in patients treated with GLP-1-based therapy who had undergone endarterectomy [22].”
BackgroundSequence Variants of SIRT6 Gene Promoter in Myocardial Infarction
Wang, L., Ma, L., Pang, S., Huang, J. A., & Yan, B. (2016) · Genetic Testing and Molecular Biomarkers · doi:10.1089/gtmb.2015.0188 · Cited by 13
“In diabetic atherosclerotic plaques, SIRT6 levels are significantly reduced compared to nondiabetic plaques (Balestrieri et al. , 2015).”
Grannes, H., Ueland, T., Simeone, P., Liani, R., Guagnano, M. T., Aukrust, P., Michelsen, A. E., Birkeland, K. I., Castelnuovo, A. F. D., Cipollone, F., et al. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02237-8 · Cited by 13
“Carotid plaque inflammation is mitigated in patients treated with GLP-1RAs [35], pointing to reduced inflammation as a possible mechanism underlying the reduction in cardiovascular risk.”
BackgroundIncretin-based therapy: a new horizon in diabetes management
Zarei, M., Vaighan, N. S., Farjoo, M. H., Talebi, S., & Zarei, M. (2024) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-024-01479-3 · Cited by 13
“Incretin treatment, specifically with GLP-1RAs, is linked to stable plaque characteristics, showing increased collagen and sirtuin-6, with reduced inflammation and oxi - dative stress in carotid plaques from diabetic patients [ 137].”
Huang, C., Wang, W., Sung, S., Chen, C., Lip, G. Y. H., Cheng, H., & Chiang, C. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14819 · Cited by 13
Diabetes, Incretin Therapy and Thoracic Aortic Aneurysm – What Does the Evidence Show?
Krizhanovskii, C., & Franco‐Cereceda, A. (2018) · Current Vascular Pharmacology · doi:10.2174/1570161116666180828155622 · Cited by 10
Munkhaugen, J., Hjelmesaeth, J. S., Otterstad, J. E., Helseth, R., Sollid, S. T., Gjertsen, E., Gullestad, L. L., Perk, J., Moum, T., Husebye, E., et al. (2018) · BMC Cardiovascular Disorders · doi:10.1186/s12872-018-0896-z · Cited by 10
Divya, K. P., Kanwar, N., Anuranjana, P. V., Kumar, G., Beegum, F., George, K. T., Kumar, N., Nandakumar, K., & Kanwal, A. (2024) · Cardiovascular Toxicology · doi:10.1007/s12012-024-09858-1 · Cited by 12
“The reduction in SIRT6 proteins is further attributed to an increase in oxidative stress and inflammation in diabetic conditions [158].”
Regulation of cardiovascular diseases by histone deacetylases and NADPH oxidases
Yan, H. M., Yin, Y., Zhou, Y., Li, Z., Li, Y., Ren, L., Wen, J., & Wang, W. (2024) · Redox Biology · doi:10.1016/j.redox.2024.103379 · Cited by 11
“SIRT6 expression is decreased in the lesions of atherosclerosis from human patients and ApoE (cid:0) / (cid:0) mice [84,85].”
BackgroundAbdelfattah, A. M., Abdelnour, H. M., Askar, E. M., Abdelhamid, A. M., & Elgarhi, R. I. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.177741 · Cited by 9
Bernardini, F., Nusca, A., Coletti, F., Porta, Y. L., Piscione, M., Vespasiano, F., Mangiacapra, F., Ricottini, E., Melfi, R., Cavallari, I., et al. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15071858 · Cited by 9
“Hence, GLP-1RA-treated plaques presented more extensive collagen content and sirtuin-6 expression, a transcription factor involved in inflammation and endothelial function, and less inflammatory and oxidative stress [140].”
BackgroundCecchini, A. L., Biscetti, F., Manzato, M., Sasso, L. L., Rando, M. M., Nicolazzi, M. A., Rossini, E., Eraso, L. H., DiMuzio, P. J., Massetti, M., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242216099 · Cited by 11
Villikudathil, A. T., McGuigan, D. H., & English, A. R. (2024) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2024.103086 · Cited by 8
Cardiovascular effects of tirzepatide
Sumithran, P., Russell, A. W., & Zoungas, S. (2025) · Journal of Endocrinology · doi:10.1530/joe-24-0259 · Cited by 12
Glucagon-like peptide-1 receptor agonists and cardiovascular disease: from LEADER to EXSCEL
Torekov, S. S. (2018) · Cardiovascular Research · doi:10.1093/cvr/cvy124 · Cited by 10
Medical and Surgical Obesity Treatments and Atherosclerosis: Mechanisms beyond Typical Risk Factors
Bostrom, J., Mottel, B. H., & Heffron, S. P. (2021) · Current Atherosclerosis Reports · doi:10.1007/s11883-021-00961-0 · Cited by 8
Sirtuin6 and Lipoxin A4 levels are decreased in severe periodontitis
Çekici, A., Şahinkaya, S., Donmez, M. F., Türkmen, E., Balcı, N., & Toygar, H. U. (2023) · Clinical Oral Investigations · doi:10.1007/s00784-023-05330-6 · Cited by 7
“It has been reported that SIRT6 expression in atherosclerotic lesions of type 2 diabetes patients was down-regulated, and the decreased SIRT6 expression was related with increased oxidative stress and inflammation [28].”
BackgroundBrowning of Adipose Tissue and Sirtuin Involvement
Favero, G., Krajčíková, K., Bonomini, F., Rodella, L. F., Tomečková, V., & Rezzani, R. (2018) · InTech eBooks · doi:10.5772/intechopen.74760 · Cited by 9
PCSK9 inhibition ameliorates microplastic-induced endothelial redox imbalance via SIRT6 modulation
D’Onofrio, N., Donisi, I., Vecchio, V. D., Prattichizzo, F., Pellegrini, V., Barbieri, M., Ceriello, A., Marfella, R., Paolisso, G., & Balestrieri, M. L. (2025) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-025-00838-z · Cited by 7
“The nuclear SIRT6 plays a crucial role in the protection against inflammation, oxidative stress, premature endothelial senescence, and atherosclerotic plaque development [31–33].”
Self-citationRole of sirtuins in attenuating plaque vulnerability in atherosclerosis
Velpuri, P., Rai, V., & Agrawal, D. K. (2023) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-023-04714-2 · Cited by 11
“In a study measuring SIRT6 expression in diabetic patients, SIRT6 is very much involved with the inflammatory pathways as it is expressed significantly higher in non-diabetics [88].”
BackgroundCollaborators, S. O. P. E. O. A. O. D. A. (.-A., Irie, Y., Katakami, N., Mita, T., Takahara, M., Matsuoka, T., Gosho, M., Watada, H., & Shimomura, I. (2018) · Diabetes Therapy · doi:10.1007/s13300-018-0367-7 · Cited by 5
“and less inflammation and oxidative stress, indicating a more stable plaque phenotype [25].”
BackgroundContemporary choice of glucose lowering agents in heart failure patients with type 2 diabetes
Katsiki, N., Kazakos, K., & Triposkiadis, F. K. (2022) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2022.2143263 · Cited by 6
Epigenetic Mechanisms of Cardioprotection: Focus is on Activation of Sirtuins
Айтбаев, К. А., Murkamilov, I. T., Абдилалимовна, М. Ж., Kudaibergenova, I., & Yusupov, F. A. (2021) · The Russian Archives of Internal Medicine · doi:10.20514/2226-6704-2021-11-6-424-432 · Cited by 6
“Так, в каротидных атеросклеротических бляшках пациентов с диабетом 2 типа экспрессия SIRT6 была снижена по сравнению с бляшками от недиабетических пациентов [6].”
InfluentialSirtuins and chemokines as markers of replicative and induced senescence of human endotheliocytes
Savitskiy, D. V., Linkova, N. S., Kozhevnikova, E. O., Kozlov, K. L., Paltseva, E. M., & Kvetnaia, T. V. (2022) · Бюллетень Восточно-Сибирского научного центра Сибирского отделения Российской академии медицинских наук · doi:10.29413/abs.2022-7.5-2.2 · Cited by 5
GLP-1 receptor agonists, carotid atherosclerosis and retinopathy
Rizzo, M., Nikolić, D., Pace, F. D., Παπάνας, Ν., & Montano, N. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1342810 · Cited by 5
“The findings indicate on beneficial effects of GLP-1RA on morphological and compositional characteristics of a plaque phenotype through the sirtuin 6 pathway [7].”
BackgroundSelf-citationAll-cause Mortality of High-normal Random Blood Glucose using Basic Demographics
Saith, S. E., & Tang, J. (2016) · Journal of Cardiovascular Diseases & Diagnosis · doi:10.4172/2329-9517.1000248 · Cited by 5
“T2DM may be a trigger for worse prognosis in atherosclerotic lesions [8].”
BackgroundNtika, S., Jois, H., Lång, K., Olsson, C., Franco‐Cereceda, A., Björck, H. M., & Krizhanovskii, C. (2021) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd8110143 · Cited by 4
“GLP-1R activation has previously been shown to promote Th2 responses through upregulation of sirtuin 6 (SIRT6) [30].”
BackgroundZwaan, E. M., Ijsselmuiden, A. J. J., Holtzer, C. A. J., van Geuns, R., van Royen, N., Moerman, E., Amoroso, G., Ritt, M. J. P. F., Schreuders, T. A. R., & Kofflard, M. J. M. (2017) · JOURNAL OF HEART AND CARDIOLOGY · doi:10.15436/2378-6914.17.1540 · Cited by 4
“Diabetes may condition the prognosis of acute coronary syndromes and when regulated tight during the procedure it up-regulates the endothelial progenitor cell level and differentiation in patients going through an acute ST-elevation myocardial infarction[21,22].”
BackgroundRafi, M. S. H., Ivy, S. C., & Dewan, S. M. R. (2025) · Health Science Reports · doi:10.1002/hsr2.71376 · Cited by 5
“GLP1 ‐ RAs have demonstrated the ability to reduce major adverse cardiovascular events (MACE) and directly influence atherosclerotic plaques by downregulating the expression of inflammatory and oxidative stress ‐ related molecules, along with apoptotic indicators [42, 43].”
Liu, F., Wang, X., Geng, H., Bu, H., Wang, P., Plaen, I. G. D., Yang, H. B., Qian, J., & Tan, X. (2020) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00335.2019 · Cited by 3
Endothelial Dysfunction, Molecular Biology, Physiopathology, Diagnosis, and Treatment
Páez, F. G., & Pimentel, J. E. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.107481 · Cited by 3
Balestrieri, M. L., Rizzo, M. R., Barbieri, M., Paolisso, P., D’Onofrio, N., Giovane, A., Servillo, L., Paolisso, G., & Marfella, R. (2015) · Diabetes · doi:10.2337/db14-1676 · Cited by 3
“We agree with Yu and Sun (1) that sirtuin 6 (SIRT6) was not only implicated in the repression of inflammation (2), oxidative stress, tumor, and aging (3) but also functioned as an oncogene in the epidermis (4).”
BackgroundInfluentialSelf-citationMaier, G. A., Hennig, B., Rathmann, W., & Kuss, O. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70523 · Cited by 2
“31 Targeting these distinct pathways of cardiorenal pathophysiology may explain the observed benefits.”
Downregulation of SIRT6 and NMNAT2 is associated with proliferative diabetic retinopathy.
Chen, H., Zhang, X., Liao, N., Ji, Y., Mi, L., Gan, Y., Su, Y., & Wen, F. (2023) · PubMed Central · Cited by 4
Akter, R., Noor, F., Tonmoy, H. S., & Ahmed, A. (2025) · Biochemical Pharmacology · doi:10.1016/j.bcp.2025.116787 · Cited by 2
Chawla, D., Kar, R., Puri, D., & Madhu, S. V. (2023) · GSC Biological and Pharmaceutical Sciences · doi:10.30574/gscbps.2023.22.3.0094 · Cited by 2
GLP-1 receptor agonism in cardiovascular disease prevention
Saleh, H. (2025) · Asia-Pacific Journal of Pharmacotherapy & Toxicology · doi:10.32948/ajpt.2024.11.22 · Cited by 1
Tirzepatide vs. semaglutide: clinical decision-making in the GLP-1 landscape
Mondoh, A., Crotty, M., & le Roux, C. W. (2025) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2025.2601060 · Cited by 3
“Preclinical evidence shows that GLP-1RAs exert anti-inflammatory and anti-apoptotic effects within the vascular wall, thereby enhancing the stability of atherosclerotic lesions and reducing the risk of plaque rupture, a primary cause of acute cardiovascular events [27].”
Obradovic, M. M., Radovanović, J., Stanimirović, J., Zarić, B. L., & Isenović, E. R. (2025) · Acta Biochimica et Biophysica Sinica · doi:10.3724/abbs.2025255 · Cited by 1
Gao, J., Huang, P., & Zhang, Y. (2026) · Clinical Epigenetics · doi:10.1186/s13148-026-02072-6 · Cited by 1
Corrao, S., Orlando, V., Manno, S. B., Cangialosi, V., & Argano, C. (2026) · Internal and Emergency Medicine · doi:10.1007/s11739-026-04281-6 · Cited by 1
“Compared to normoglycaemic people (NGs), people with diabetes have impaired glucose homeostasis and insulin resistance, which could cause the overexpression of inflammatory molecules at the level of the atherosclerotic plaque, leading to the rupture of unstable plaques and MACE [104].”
Marfella, R., Fumagalli, C., Marfella, L. V., Furbatto, F., Fenti, A., Paolisso, P., Sardu, C., Prattichizzo, F., Iovino, P., & Mauro, C. (2026) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2026.03.050 · Cited by 1
Self-citationLamos, E. M., & Davis, S. N. (2016) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2016.1216974 · Cited by 1
“The observed benefit could potentially be related to a modification of atherosclerotic vascular disease as previously shown in small, and mainly animal, studies [23,24].”
ResultD’Onofrio, N., Servillo, L., Giovane, A., Casale, R., Cautela, D., Castaldo, D., & Balestrieri, M. L. (2017) · Translational Medicine Reports · doi:10.4081/tmr.6577 · Cited by 1
Self-citationChaulin, A. M., & Grigoryeva, J. (2020) · International Journal of Applied and Fundamental Research (Международный журнал прикладных и фундаментальных исследований) · doi:10.17513/mjpfi.13159 · Cited by 5
GENETIC PREDICTORS OF VASCULAR AGING
Chepurnova, N. S., Jushhuk, V. N., Kozaeva, O. A., Markelova, E. V., & Shumatov, V. B. (2022) · Современные проблемы науки и образования · doi:10.17513/spno.32111 · Cited by 1
Xu, M., Zhang, P., Lv, W., Chen, Y., Chen, M., Leng, Y., Hu, T., Wang, K., Zhao, Y., Shen, J., et al. (2023) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2023.127003 · Cited by 1
GLP1-Receptor Agonists in Diabetes: Drugs, General Effects, and Cardiovascular Impact
Breder, I. S. S., & Sposito, A. C. (2020) · Springer eBooks · doi:10.1007/978-3-030-53370-0_51 · Cited by 1
Katsuumi, G., & Minamino, T. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-822514-1.00007-9 · Cited by 2
Çekici, A., Şahinkaya, S., Donmez, M. F., Türkmen, E., Balcı, N., & Toygar, H. U. (2022) · Research Square · doi:10.21203/rs.3.rs-1729628/v1 · Cited by 1
Yu, W., & Sun, Y. T. (2015) · Diabetes · doi:10.2337/db14-1633
“(1) and thought that SIRT6 was a two-edged sword in health and disease.”
BackgroundMasaki, T. (2016) · JOURNAL OF HEART AND CARDIOLOGY · doi:10.15436/2378-6914.16.1000
Revascularization of chronic total occluded coronary arteries: probable benefits and possible harms
Connell, J. L. O., de Almeida, R. P., & Roever, L. (2017) · Interventional Cardiology · doi:10.4172/interventional-cardiology.1000560
The Endothelial Progenitor Cell Dysfunction: The Missed Predictor of Heart Failure Outcomes?
(2017) · ARC Journal of Cardiology · doi:10.20431/2455-5991.0302001
Shi, H., Peng, M., Liu, Y., Kan, Z., Li, W., & Yang, T. (2021) · International Journal of Clinical Practice · doi:10.1111/ijcp.14213
RetractedFaculty Opinions recommendation of The role of sirtuins in antioxidant and redox signaling.
Ji, L. L. (2021) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.731078139.793582081
Villikudathil, A. T., McGuigan, D. H., & English, A. R. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.4814934
AVC, nouveaux traitements : place des agonistes du récepteur du GLP-1
Vergès, B. L. (2024) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2024.07.005
Are GLP-1 Analogues a New Solution for the Treatment of NAFLD?
Sudoł, M., Dąbek, K., Ochwat, M., Piekarska, M., Skowronek, A., Kajtel, A., Mierzwa, G., & Sudoł, Z. (2024) · Quality in Sport · doi:10.12775/qs.2024.35.56304 · Cited by 1
Grannes, H., Ueland, T., Simeone, P., Liani, R., Guagnano, M. T., Aukrust, P., Michelsen, A. E., Birkeland, K., di Castelnuovo, A., Cipollone, F., et al. (2024) · Figshare · doi:10.6084/m9.figshare.25720188
Marfella, R., Prattichizzo, F., Sardu, C., Rambaldi, P. F., Fumagalli, C., Marfella, L. V., Grotta, R. L., Frigé, C., Pellegrini, V., D’Andrea, D., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26664109
Self-citationDong, Z., Zhou, Y., Gao, Y., Guo, R., He, X., Deng, Y., Chen, Y., Zhu, Q., Wei, J., & Guo, Z. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1784874
Metadata
- Authors
- Balestrieri, M. L., Rizzo, M. R., Barbieri, M., Paolisso, P., D’Onofrio, N., Giovane, A., Siniscalchi, M., Minicucci, F., Sardu, C., D’Andrea, D., Mauro, C., Ferraraccio, F., Servillo, L., Chirico, F., Caiazzo, P., Paolisso, G., & Marfella, R.
- Affiliations
- University of Campania "Luigi Vanvitelli" (IT)
- Ospedale Antonio Cardarelli (IT)
- Corresponding author
- Marfella, Raffaele
- ORCID
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2014-10-16
- Volume
- 64
- Issue
- 4
- Pages
- 1395-1406
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- OpenAlex
- W2116296155
- Cited by
- 196
- References
- 40
- Citations by year
- 2026: 5 · 2025: 12 · 2024: 16 · 2023: 14 · 2022: 19 · 2021: 28 · 2020: 14 · 2019: 22 · 2018: 20 · 2017: 19 · 2016: 17 · 2015: 10
- FWCI
- 7.81
- Type
- journal article
- Language
- en
- Open access
- Licence
- other-oa
- Locations
- Diabetes (publishedVersion)
- PubMed (publishedVersion)
- Archivio Istituzionale della Ricerca - Università degli Studi della Campania "Luigi Vanvitelli" (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- INFM-OAR (INFN Catania) (submittedVersion, other-oa)
- Topics
- Health Sciences › Medicine › Geriatrics and Gerontology › Sirtuins and Resveratrol in Medicine
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Physiology (medical) › Nitric Oxide and Endothelin Effects
- Keywords
- SIRT6, diabetic atherosclerosis, atherosclerotic plaque inflammation, incretin-based therapy, GLP-1 receptor agonists, DPP-4 inhibitors, carotid plaque, plaque stability, oxidative stress, collagen content, endothelial progenitor cells, endothelial cells, high glucose, NF-κB, liraglutide, type 2 diabetes
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Aged, Carotid Arteries, Collagen, Diabetes Mellitus, Type 2, Female, Humans, Inflammation, Male, Middle Aged, Endarterectomy, Carotid, Receptors, Glucagon, Oxidative Stress, Sirtuins, Incretins, Dipeptidyl-Peptidase IV Inhibitors, Plaque, Atherosclerotic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.